Results 181 to 190 of about 2,423,182 (300)

Patch Testing in Paediatric Drug Hypersensitivity Reactions: Current Evidence and Clinical Implications. [PDF]

Contact Dermatitis
Simonetti G, Catamerò F, Liccioli G, Tomei L, Barni S, Giovannini M, Sarti L, Mori F.   +7 more
europepmc   +1 more source

Botulinum Toxin for First Bite Syndrome: A Symptom‐Guided “Follow‐The‐Pain” Injection Strategy

Head &Neck, EarlyView.
ABSTRACT Background To evaluate botulinum toxin type A (BoNT‐A) for First Bite Syndrome (FBS) and assess a symptom‐guided “Follow‐the‐Pain” (FTP) injection strategy in patients with incomplete response to standard treatment. Methods Consecutive patients with postoperative FBS were treated with ultrasound‐guided intraparotid BoNT‐A injection.
Rosario Marchese‐Ragona, Gianmarco Giunta, Daniela Adamo, Elisabetta Zanoletti, Daniele Manfredini, Domenico Antonio Restivo   +5 more
wiley   +1 more source

JAK inhibition may prevent drug hypersensitivity reactions. [PDF]

JCI Insight
Hua X, Shah PN, Velasquez GA, Sidky L, Romar GA, Boer LW, Hickerson N, Cui TQ, Repetto F, Waldman A, Liang MG, Marcoux JP, Sellars M, Barrera V, Schmidt BA, Mostaghimi A, Foreman RK, Lian CG, Divito SJ.   +18 more
europepmc   +1 more source

Clinical and behavioral determinants in pediatric non-immediate drug hypersensitivity: Low confirmation but persistent avoidance. [PDF]

Pediatr Allergy Immunol
Can Bostan O, Soyer O, Papadopoulos M, Tsabouri S.   +3 more
europepmc   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source

Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis. [PDF]

Clin J Gastroenterol
Madarame A, Kanda R, Shimizu Y, Itoi T.
europepmc   +1 more source

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Research Progress and Precision Diagnosis‐Therapy Under the Integrated Neuro–Immune–Metabolic–Microbiota Axis Framework

iMetaMed, EarlyView.
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is increasingly recognized as a systemic disorder rather than a purely local prostate disease. The diagram illustrates the transition from the traditional local prostate‐centered model to a multi‐axis systemic framework involving clinical heterogeneity, local prostatic inflammation, systemic ...
Kun Wang, Jinfei Liu, Qiangsheng Wang, Lei Fan, Ziang Li, Xuexin Yu, Yonghao Chen, Xiaofan Lu, Guiyi Liao, Jialin Meng, Yu Guan   +10 more
wiley   +1 more source

Methotrexate-Induced Drug Hypersensitivity Syndrome Presenting With Acute Cerebral Infarction in End-Stage Renal Disease: A Case Report. [PDF]

Clin Case Rep
Mu L, Yu C, Shi JY, Dong ZY, Yi FY, Li YY, Zhang SJ.   +6 more
europepmc   +1 more source

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

iNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai, Jia Deng, Hongquan Wang, Yao Yao, Tao Wang   +4 more
wiley   +1 more source

NSAID drug hypersensitivity in a United States-based population: An assessment of quality of life. [PDF]

J Allergy Clin Immunol Glob
Mahajan S, Batra N, Trickett J, Chow TG.
europepmc   +1 more source